Safety Syringes, one of the leading manufacturers of needlestick protection devices, has launched a tamper-evident version of its UltraSafe Passive Delivery System to help prevent or make evident attempts for counterfeiting and adulteration of unit dose, pre-filled glass syringe pharmaceutical presentations.
The company claims this is the industry's first and only product that combines a tamper-evident feature with passive needlestick prevention for pre-filledglass syringes.
The new version of the product "will help maintain the integrity of drugs by preventing adulteration initiated by those who wish to do harm to end-users or want to profit by repackaging and reselling important pharmaceutical products," said the company's CEO, Christer Andreasson.
The UltraSafe Delivery System has been on the market since 1999, and customers include Abbott Laboratories, Amgen, Bayer, Ortho Clinical Diagnostics and Pfizer.
Each year, 600,000-1,000,000 accidental needlesticks are reported in the USA alone. Even more alarming is that it is estimated that only one third of all incidents are reported.
Eighty-nine per cent of healthcare workers who have HIV or hepatitis B virus contracted the disease from needlestick-induced infections, according to Safety Syringes.